BioSpace News Archive

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that the first patient has been dosed in the Phase 1/2 trial of ZN-c3, the Company’s oral WEE1 inhibitor product candidate, in combination with gemcitabine, a chemotherapy used to treat certain malignant tumors, in pediatric and adult patients with relapsed or refractory osteosarcoma.

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 SURPASS trial in multiple solid tumors to be presented in a digital poster at the upcoming European Society for Medical Oncology (ESMO) annual meeting.

Instil Bio, Inc. today reported clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate DELTA-1

Protara Therapeutics, Inc. today announced the completion of a retrospective prevalence study designed to enhance understanding of the incidence of intestinal failure associated liver disease (IFALD) in patients dependent on parenteral nutrition (PN).

Max BioPharma , Inc. ( www.maxbiopharma.com ) recently published an article that reported the efficacy of its anti-fibrotic and anti-inflammatory oxysterol lead compound, Oxy210, in the peer-reviewed journal, Endocrinology, Diabetes & Metabolism .

RedHill Biopharma Ltd. today announced that South Africa has joined the U.S. in approving the Phase 2/3 study with novel, once-daily, orally-administered pill RHB-107 (upamostat)[1] for non-hospitalized patients with symptomatic COVID-19.

AIVITA Biomedical, Inc. today announced results from its Phase 2 clinical study testing AIVITA’s anti-SARS-CoV-2 Vaccine Enabling Kit, which allows ny minimally-equipped facility to make personalized COVID-19 vaccines during the course of 2 patient visits one week apart.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the initiation of the first site for its pivotal ReMEDy2 Trial, a Phase 2/3 clinical study of DM199 for the treatment of acute ischemic stroke (AIS).

Sorrento Therapeutics, Inc., announced that Dr. Henry Ji, Chairman and CEO, will participate in the H.C. Wainwright 23rd Global Investment Conference.

ImmunityBio, Inc., a clinical-stage immunotherapy company, announced updated data from an ongoing bladder cancer trial showing sustained complete response rates in patients with BCG-unresponsive non-muscle invasive carcinoma in situ bladder cancer.